A practical reference on IGF-1: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-02-16. Anything still debated is marked as such rather than presented as settled.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (with DAC) | ~3647 Da | Calculated from the full amino acid sequence |
| Molecular weight (without DAC) | ~3368 Da | Mod GRF(1-29) variant |
| Appearance | White lyophilized powder | Typical form supplied for research |
| Solubility | Soluble in water | Dissolves in aqueous buffers |
| Receptor target | GHRH receptor | Expressed on pituitary somatotroph cells |
Peptide degradation proceeds mainly through hydrolysis, oxidation of methionine, and deamidation of asparagine or glutamine residues. The maleimide group on the albumin-binding variant can also react with thiols or hydrolyze in aqueous media. Because these pathways accelerate with temperature and pH extremes, handling conditions strongly influence measured stability. Stability data in the public literature are limited and often generated under differing conditions, so general statements about shelf life should be read as approximate.
Research material is normally supplied as a freeze-dried powder in sealed vials. In that state the peptide is comparatively robust, but prolonged exposure to warmth, moisture, or light accelerates degradation. Storage at minus twenty degrees Celsius or lower, with desiccant and protection from light, is the commonly described practice. Vials should be allowed to reach room temperature before opening to limit condensation on the powder. Moisture uptake during handling is a recognized source of variability in later measurements.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
==== Liquid ==== Metafluids offer programmable properties such as viscosity, compressibility, and optical. One approach employed 50-500 micron diameter air-filled elastomer spheres suspended in silicon oil. The spheres compress under pressure, and regain their shape when the pressure is relieved. Their properties differ across those two states. Unpressurized, they scatter light, making them opaque. Under pressure, they collapse into half-moon shapes, focusing light, and becoming transparent. The pressure response could allow them to act as a sensor or as a dynamic hydraulic fluid. Like cornstarch, it can act as either a Newtonian or a non-Newtonian fluid. Under pressure, it becomes non-Newtonian – meaning its viscosity changes in response to shear force.
The genetic code expansion described above is in vivo. An alternative is the change of coding in vitro translation experiments. This requires the depletion of all tRNAs and the selective reintroduction of certain aminoacylated-tRNAs, some chemically aminoacylated.
. They are calculated for the Gaussian distribution of asperities, which have been shown to be unrealistic for engineering surface but can be assumed where friction, load carrying capacity or real contact area results are not critical to the analysis.
Sources: en.wikipedia.org
== Notable employees == Former British Prime Minister Margaret Thatcher worked as a chemist for the company prior to becoming a barrister and then a Conservative Party MP. While working for the company she helped develop methods for preserving ice cream. Peter Bird began work operating the LEO computer and rose to be a director of Lyons Computer Services. He later wrote a history of the company and its computers.
==== The locus of power and organized crime ==== Some espouse that all organized crime operates at an international level, though there is currently no international court capable of trying offenses resulting from such activities (the International Criminal Court's remit extends only to dealing with people accused of offenses against humanity, e.g., genocide). If a network operates primarily from one jurisdiction and carries out its illicit operations there and in some other jurisdictions it is 'international,' though it may be appropriate to use the term 'transnational' only to label the activities of a major crime group that is centered in no one jurisdiction but operating in many. The understanding of organized crime has therefore progressed to combined internationalization and an understanding of social conflict into one of power, control, efficiency risk and utility, all within the context of organizational theory. The accumulation of social, economic and political power have sustained themselves as a core concerns of all criminal organizations:
Birches native to Eurasia include Betula albosinensis – Chinese red birch (northern + central China) Betula alnoides – alder-leaf birch (China, Himalayas, northern Indochina) Betula ashburneri – (Bhutan, Tibet, Sichuan, Yunnan Provinces in China) Betula baschkirica – (eastern European Russia) Betula bomiensis – (Tibet) Betula browicziana – (Turkey and Georgia) Betula buggsii – (China) Betula calcicola – (Sichuan + Yunnan Provinces in China) Betula celtiberica – (Spain and Portugal) Betula chichibuensis – (Chichibu region of Japan) Betula chinensis – Chinese dwarf birch (China, Korea) Betula coriaceifolia – (Uzbekistan) Betula corylifolia – (Honshu Island in Japan) Betula costata – (northeastern China, Korea, Primorye region of Russia) Betula cylindrostachya – (Himalayas, southern China, Myanmar) Betula dahurica – (eastern Siberia, Russian Far East, northeastern China, Mongolia, Korea, Japan) Betula delavayi – (Tibet, southern China) Betula ermanii – Erman's birch (eastern Siberia, Russian Far East, northeastern China, Korea, Japan) Betula falcata – (Tajikistan) Betula fargesii – (Chongqing + Hubei Provinces in China) Betula fruticosa – (eastern Siberia, Russian Far East, northeastern China, Mongolia, Korea, Japan) Betula globispica – (Honshu Island in Japan) Betula gmelinii – (Siberia, Mongolia, northeastern China, Korea, Hokkaido Island in Japan) Betula grossa – Japanese cherry birch (Japan) Betula gynoterminalis – (Yunnan Province in China) Betula honanensis – (Henan Province in China) Betula humilis or Betula kamtschatica – Kamchatka birch platyphylla (northern + central Europe, Siberia, Kazakhstan, Xinjiang, Mongolia, Korea) Betula insignis – (southern China) Betula karagandensis – (Kazakhstan) Betula klokovii – (Ukraine) Betula kotulae – (Ukraine) Betula luminifera – (China) Betula maximowicziana – monarch birch (Japan, Kuril Islands) Betula medwediewii – Caucasian birch (Turkey, Iran, Caucasus) Betula megrelica – (Republic of Georgia) Betula microphylla – (Siberia, Mongolia, Xinjiang, Kazakhstan, Kyrgyzstan, Uzbekistan) Betula nana – dwarf birch (northern + central Europe, Russia, Siberia, Greenland, Northwest Territories of Canada)) Betula pendula – silver birch (widespread in Europe and northern Asia; Morocco; naturalized in New Zealand and scattered locations in US + Canada) Betula platyphylla – (Betula pendula var. platyphylla) – Siberian silver birch (Siberia, Russian Far East, Manchuria, Korea, Japan, Alaska, western Canada) Betula potamophila – (Tajikistan) Betula potaninii – (southern China) Betula psammophila – (Kazakhstan) Betula pubescens – downy birch, also known as white, European white or hairy birch (Europe, Siberia, Greenland, Newfoundland; naturalized in scattered locations in US) Betula raddeana – (Caucasus) Betula saksarensis – (Khakassiya region of Siberia) Betula saviczii – (Kazakhstan) Betula schmidtii – (northeastern China, Korea, Japan, Primorye region of Russia) Betula sunanensis – (Gansu Province of China) Betula szechuanica – (Betula pendula var. szechuanica)—Sichuan birch (Tibet, southern China) Betula tianshanica – (Kazakhstan, Kyrgyzstan, Tajikistan, Uzbekistan, Xinjiang, Mongolia) Betula utilis – Himalayan birch (Afghanistan, Central Asia, China, Tibet, Himalayas) Betula wuyiensis – (Fujian Province of China) Betula zinserlingii – (Kyrgyzstan) Note: many American texts have B. pendula and B. pubescens confused, though they are distinct species with different chromosome numbers.
The enzyme has been characterised from mammalian liver, Escherichia coli and yeast. Humans have three protein isoforms: NMNAT1 (widespread), NMNAT2 (predominantly in brain), and NMNAT3 (highest in liver, heart, skeletal muscle, and erythrocytes). Mutations in the NMNAT1 gene lead to the LCA9 form of Leber congenital amaurosis. Mutations in NMNAT2 or NMNAT3 genes are not known to cause any human disease. NMNAT2 is critical for neurons: loss of NMNAT2 is associated with neurodegeneration. All NMNAT isoforms reportedly decline with age.
Sources: en.wikipedia.org
Tequila is made from the blue agave plant, primarily in the area surrounding the town of Tequila 65 km (40 mi) northwest of Guadalajara, and in the Jaliscan Highlands (Los Altos de Jalisco) of the central western Mexican state of Jalisco. Aside from its geographical distinction, tequila is differentiated from other varieties of mezcal in that all of the agave used in tequila is blue agave, and the methods of production are different. The red volcanic soils in the region of Tequila are well suited for growing the blue agave, and more than 300 million plants are harvested there each year. Agave grows differently depending on the region. Blue agaves grown in the highland Los Altos region are larger and sweeter in aroma and taste. Agaves harvested in the valley region have a more herbaceous fragrance and flavor. Due to its historical and cultural importance, the region near Tequila was declared a UNESCO World Heritage Site in 2006, the Agave Landscape and Ancient Industrial Facilities of Tequila. Planting, tending, and harvesting the agave plant remains a manual effort, largely unchanged by modern farm machinery and relying on centuries-old expertise. The people who harvest it, the jimadores [ximaˈðoɾes], passed down the knowledge of how the plants should be cultivated from generation to generation. By regularly trimming any quiotes [ˈkjotes] (a stalk at the center of the plant that could grow several meters high if not cut back), the jimadores prevent the agave from flowering and dying early, allowing it to fully ripen.
{\displaystyle {\text{eGFR}}={\text{170}}\ \times \ [{\text{Serum Creatinine}}]^{-0.999}\ \times \ {\text{Age}}^{-0.176}\ \times {\text{[0.762 if Female]}}\ \times {\text{[1.180 if Black]}}\ \times \ {\text{BUN}}^{-0.170}\ \times \ {\text{Albumin}}^{+0.318}}
There were also unpublicised transfers of technology, including the engagement of a US company, Continental Electronics, to design and build a new VLF communications station at Tirunelveli in Tamil Nadu, which was commissioned in the late 1980s.
Sources: en.wikipedia.org
The synthetic peptide keeps the receptor-binding region of GHRH but carries substitutions that resist enzymatic cleavage. In the DAC version, an added group also anchors the molecule to albumin, extending its presence in the bloodstream.
The maleimide group forms a covalent link with albumin, an abundant blood protein. This attachment slows clearance, so a single administration persists much longer than the unmodified peptide. The feature is the main reason the two variants are handled differently in study design.
It is not an approved therapeutic product in major regulatory jurisdictions. It appears in research chemical catalogs and scientific literature rather than pharmacy shelves. Clinical development was limited and did not reach approval.
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.